OncoMatch/Clinical Trials/NCT03392233
Stereotactic Body Radiation Therapy for Spinal Metastases in Favorite Tumors
Is NCT03392233 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for breast cancer.
Stereotactic Body Radiation Therapy(SBRT) for spinal metastases has been proved a good results in pain relieve and local control, However,the longterm of efficacy and safety of this regimen is unclear.The purpose of the study is to evaluate the longterm outcome of this therapeutic regimen in selective patients who will be survival more than 2 years.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Prostate Cancer
Non-Small Cell Lung Carcinoma
Disease stage
Metastatic disease required
Performance status
WHO 0–2
Demographics
Prior therapy
Cannot have received: radiation therapy
Lab requirements
Blood counts
leukocytes ≥ 3.0 x10^9/l; anc ≥ 1.5 x10^9/l; platelet count ≥ 100 x10^9/l; hemoglobin ≥ 9g/dl
Kidney function
serum creatinine ≤ 1.5 x uln
Liver function
total bilirubin ≤1.5 x uln; alt ≤ 3 x uln; ast ≤ 3 x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT03392233 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 85 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages